| Male Reproductive System Neoplasm altered in cohorts of …ALTERED_INderived200 of 242show all (up to 200) |
|---|
| ← altered in cohorts of | KRAS 255 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ANO2 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGDIB 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ART4 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF7IP 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C12orf60 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAPZA3 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DERA 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMP1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPS8 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ERP27 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM234B 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPRC5D 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRIN2B 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSG1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GUCY2C 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | H2AJ 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | H4-16 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HEBP1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMO3 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MGP 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MGST1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDE3A 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDE6H 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIK3C2G 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLBD1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLCZ1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHA5 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTPRO 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RERG 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RERGL 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC15A5 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLCO1C1 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMCO3 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STRAP 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WBP11 254 / 263 cases (97 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCC9 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AEBP2 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APOLD1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL2L14 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BHLHE41 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD27 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD4 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDCA3 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CFAP94 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHD4 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC12A 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC12B 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC1A 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC1B 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC2B 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC7A 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLEC9A 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CMAS 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COPS7A 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CREBL2 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP16 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETFRF1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETNK1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABARAPL1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GAPDH 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNB3 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLT1B 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR162 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR19 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IAPP 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IFFO1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IRAG2 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLRC3 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLRC4 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLRD1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLRK1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAG3 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNTD1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPAR5 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRP6 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MANSC1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MLF2 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCAPD2 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTF3 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHG6 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRB2 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRH1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RASSF8 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCNN1A 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLCO1B1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLCO1B3-SLCO1B7 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM10L1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPX 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SSPN 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ST8SIA1 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAPBPL 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS2R19 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS2R50 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM52B 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP5 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YBX3 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF384 253 / 263 cases (96 %) · ssm · TCGA-TGCT | — | — | Testicular Germ Cell Tumor | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCAR2 298 / 500 cases (60 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BIN3 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C8orf58 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | XPO7 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP1 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEBP4 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIWIL2 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP3CC 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RHOBTB2 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SORBS3 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10C 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DMTN 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOK2 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EGR3 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM160B2 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HR 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDLIM2 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR3D 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | REEP4 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10A 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10D 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHMP7 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF17 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LGI3 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LOXL2 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NKX3-1 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPM2 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUDT18 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHYHIP 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | R3HCC1 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SFTPC 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC25A37 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A14 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10B 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM28 293 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENTPD4 293 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NKX2-6 292 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM7 291 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMDEC1 291 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STC1 291 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GFRA2 290 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LZTS1 289 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP6V1B2 286 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDCA2 286 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC18A1 286 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS10 284 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPL 284 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CSGALNACT1 283 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOCK5 283 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPYSL2 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EBF2 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCTD9 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEFL 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEFM 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PNMA2 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP2R2A 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADRA1A 281 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BNIP3L 281 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNRH1 281 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D4A 279 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM35 278 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRNA2 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSD3 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTK2B 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STMN4 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPHX2 276 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAT2 275 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC25 273 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESCO2 273 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAT1 273 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAH1 272 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCM1 272 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLU 271 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGL1 271 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PBK 271 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTUS1 270 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCARA3 270 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCARA5 269 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUGGC 267 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDGFRL 267 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A2 267 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELP3 265 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTMR7 262 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PNOC 262 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SGCZ 262 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSR1 261 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TUSC3 261 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNOT7 260 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF395 260 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DLC1 259 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS37A 259 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZDHHC2 259 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C8orf48 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EXTL3 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO16 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FZD3 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF20 257 / 500 cases (51 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LONRF1 257 / 500 cases (51 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IDH1 29 / 99 cases (29 %) · ssm · prad_idhmut_msk_2025 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 551 / 2,069 cases (27 %) · ssm · prad_msk_stopsack_2021 · largest of 17 cohorts | — | — | Prostate Adenocarcinoma | 17 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FRG1BP 97 / 499 cases (19 %) · ssm · prad_tcga | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TTN 151 / 1,013 cases (15 %) · ssm · prad_p1000 · largest of 8 cohorts | — | — | Prostate Adenocarcinoma | 8 | Observed | cbioportal | graph → |